SCHEMBL1868541

SCHEMBL1868541

CC1[CH]CC2CC1CCC2(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1860691 0.63
SCHEMBL847951 0.61 TSHR (0.34)
SCHEMBL1588075 0.61 TSHR (0.34)
SCHEMBL847288 0.61 TSHR (0.34)
SCHEMBL9817562 0.61 TSHR (0.34)
SCHEMBL7408718 0.58
SCHEMBL4942823 0.58
SCHEMBL24982807 0.57
SCHEMBL10580861 0.57
SCHEMBL2320997 0.56 ALDH1A1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939509-B2 Partial and full agonists of A1 adenosine receptors GILEAD SCIENCES, INC. (US) 2011-05-10 US disclosed
EP-2259790-A1 ABCA-1 ELEVATING COMPOUNDS AND THE USE THEREOF Gilead Palo Alto, Inc. (US) 2010-12-15 EP disclosed
US-20100210579-A1 PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS GILEAD PALO ALTO, INC. (US) 2010-08-19 US disclosed
US-7713946-B2 Partial and full agonists A1 adenosine receptors CV THERAPEUTICS, INC. (US) 2010-05-11 US disclosed
US-7655638-B2 2-{6-[((1R,2R)-2-hydroxycyclopentyl)amino]purin-9-yl}(4S,5S,2R,3R)-5-[(2-chloro-6-methylphenylthio)methyl]oxolane-3,4-diol; atrial fibrillation, tachycardia and atrial flutter, congestive heart failure, epilepsy, stroke, diabetes, obesity, ischemia, angina, cardiac transplant, and myocardial infarction GILEAD PALO ALTO, INC. (US) 2010-02-02 US disclosed
EP-2120954-A1 ADENOSINE DERIVATIVES AS PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS CV Therapeutics Inc. (US) 2009-11-25 EP disclosed
US-20090247557-A1 PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS GILEAD SCIENCES, INC. 2009-10-01 US disclosed
WO-2009100326-A1 ABCA-1 ELEVATING COMPOUNDS AND THE USE THEREOF CV THERAPEUTICS, INC. (US) 2009-08-13 WO disclosed
US-20090203689-A1 ABCA-1 ELEVATING COMPOUNDS AND METHODS CV THERAPEUTICS, INC. 2009-08-13 US disclosed
WO-2008077050-A1 ADENOSINE DERIVATIVES AS PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS CV THERAPEUTICS, INC. (US) 2008-06-26 WO disclosed
US-20070185051-A1 Partial and full agonists of A1 adenosine receptors GILEAD SCIENCES, INC. 2007-08-09 US disclosed
US-20070066560-A1 Partial and full agonists of A1 adenosine receptors ELZEIN ELFATIH 2007-03-22 US disclosed
US-7157440-B2 Partial and full agonists of A1 adenosine receptors CV THERAPEUTICS, INC. (US) 2007-01-02 US disclosed
US-6946449-B2 Partial and full agonists of A1 adenosine receptors CV THERAPEUTICS, INC. (US) 2005-09-20 US disclosed
US-20050020532-A1 Partial and full agonists of A1 adenosine receptors GILEAD PALO ALTO, INC. 2005-01-27 US disclosed
WO-2004007519-A1 PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS CV THERAPEUTICS, INC. (US) 2004-01-22 WO disclosed
US-20030050275-A1 Partial and full agonists of A1 adenosine receptors GILEAD PALO ALTO, INC. 2003-03-13 US disclosed